Bacillary Dysentery (Shigellosis) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Bacillary Dysentery (Shigellosis) - Pipeline Review, H1 2019’, provides an overview of the Bacillary Dysentery (Shigellosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis)

- The report reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Bacillary Dysentery (Shigellosis) therapeutics and enlists all their major and minor projects

- The report assesses Bacillary Dysentery (Shigellosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bacillary Dysentery (Shigellosis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akthelia Pharmaceuticals Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Immuron Ltd

Polyneuron Pharmaceuticals AG

Protein Potential LLC

Akthelia Pharmaceuticals Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Immuron Ltd

Polyneuron Pharmaceuticals AG

Protein Potential LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacillary Dysentery (Shigellosis) – Overview

Bacillary Dysentery (Shigellosis) – Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacillary Dysentery (Shigellosis) – Overview

Bacillary Dysentery (Shigellosis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacillary Dysentery (Shigellosis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacillary Dysentery (Shigellosis) – Companies Involved in Therapeutics Development

Akthelia Pharmaceuticals Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Immuron Ltd

Polyneuron Pharmaceuticals AG

Protein Potential LLC

Bacillary Dysentery (Shigellosis) – Drug Profiles

(shigella + typhoid) (Bivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKT-10081 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3536852A – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVXNSD-133 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious disease vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN-109 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-599 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF2a-TT15 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella (bivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella [serotype 2a] vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella [strain 53G] vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Shigetec – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacillary Dysentery (Shigellosis) – Dormant Projects

Bacillary Dysentery (Shigellosis) – Product Development Milestones

Featured News & Press Releases

Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine

Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions

Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease

Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine

Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Bacillary Dysentery (Shigellosis) – Pipeline by Akthelia Pharmaceuticals Ltd, H1 2019

Bacillary Dysentery (Shigellosis) – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2019

Bacillary Dysentery (Shigellosis) – Pipeline by GlaxoSmithKline Plc, H1 2019

Bacillary Dysentery (Shigellosis) – Pipeline by Immuron Ltd, H1 2019

Bacillary Dysentery (Shigellosis) – Pipeline by Polyneuron Pharmaceuticals AG, H1 2019

Bacillary Dysentery (Shigellosis) – Pipeline by Protein Potential LLC, H1 2019

Bacillary Dysentery (Shigellosis) – Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports